United States - English - NLM (National Library of Medicine)

remedyrepack inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride tablets are indicated: in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone is contraindicated in: - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists [e.g., methadone or laam (levo-alpha-acetylmethadol)]. - patients in acute opioid withdrawal ( see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. - any individual with acute hepatitis or liver failure.

United States - English - NLM (National Library of Medicine)

nucare pharmceuticals,inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride tablets usp 50 mg is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets usp 50 mg has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone hydrochloride is contraindicated in - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone ) or partial agonists (e.g., buprenorphine) - patients in acute opioid withdrawal (see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product.it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. naltrexone hydrochloride i

United States - English - NLM (National Library of Medicine)

alkermes, inc. - naltrexone (unii: 5s6w795cqm) (naltrexone - unii:5s6w795cqm) - naltrexone 380 mg in 4 ml - treatment with vivitrol should be part of a comprehensive management program that includes psychosocial support. vivitrol is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with vivitrol. patients should not be actively drinking at the time of initial vivitrol administration. vivitrol is indicated for the prevention of relapse to opioid dependence, following opioid detoxification. vivitrol is contraindicated in: - patients receiving opioid analgesics [see warnings and precautions (5.3)] . - patients with current physiologic opioid dependence [see warnings and precautions (5.3)] . - patients in acute opioid withdrawal [see warnings and precautions (5.3)] . - any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see warnings and precautions (5.3)] . - patients who have previously exhibited hypersensitivity to naltrexone, plg, carboxymethylcellulose, or any

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - naltrexone hydrochloride - film-coated tablet - naltrexone hydrochloride 50 mg - other nervous system drugs

Malta - English - Medicines Authority

accord healthcare limited - naltrexone hydrochloride - film-coated tablet - naltrexone hydrochloride 50 mg - other nervous system drugs

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm), bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - naltrexone hydrochloride 8 mg - contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (bmi) of: limitations of use: pregnancy category x risk summary contrave is contraindicated during pregnancy, because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard of maternal weight loss to the fetus. clinical considerations a minimum weight gain, and no weight loss, is currently recommended for all pregnant women, including those who are already overweight or obese, due to the obligatory weight gain that occurs in maternal tissues during pregnancy. human data there are no adequate and well-controlled studies of contrave in pregnant women. in clinical studies, 21 (0.7%) of 3,024 women became pregnant while taking contrave: 11 carried to term and gave b

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - naltrexone hydrochloride - film-coated tablet - 50 milligram(s) - drugs used in alcohol dependence; naltrexone

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - naltrexone hydrochloride - film-coated tablet - 50 milligram(s) - drugs used in alcohol dependence; naltrexone

United States - English - NLM (National Library of Medicine)

abbvie inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 8 mg

United States - English - NLM (National Library of Medicine)

a-s medication solutions - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride tablets usp are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets usp have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone hydrochloride is contraindicated in: - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). - patients in acute opioid withdrawal (see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. naltrexone hydrochloride is a pure opioid antagonist. it does not